Cyclophosphamide
Krabbe Disease
Masonic Cancer Center, University of MinnesotaSmall moleculePhase 2/3Dormant
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Krabbe Disease cohort.
View all 12 →
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →